Pfizer Inc. $PFE Shares Bought by Proffitt & Goodson Inc.

Proffitt & Goodson Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 23.0% in the second quarter, HoldingsChannel.com reports. The fund owned 4,257 shares of the biopharmaceutical company’s stock after buying an additional 795 shares during the quarter. Proffitt & Goodson Inc.’s holdings in Pfizer were worth $103,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Horizon Financial Services LLC acquired a new position in shares of Pfizer in the first quarter valued at approximately $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer in the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $26.27 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a 50 day moving average price of $24.76 and a 200 day moving average price of $24.14. The company has a market cap of $149.36 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 earnings per share. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on PFE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. UBS Group restated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.